Immuneering grants director Bogle 66,700 stock options

The options vest monthly beginning December 9, 2026, and become fully vested and exercisable on November 9, 2029.

Available on EDGAR 11/09/2026 - 04:31 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:31 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Immuneering Corp (IMRX) director Grant C. Bogle received a grant of 66,700 stock options on November 9, 2026, with an exercise price of $3.65 per share. The options vest in equal monthly installments over a three-year period commencing December 9, 2026, and will be fully vested and exercisable on November 9, 2029; they expire November 9, 2036.

Insider Trade Summary

Grant/Award: 66,700 shares

Grant/Award 1 txn

Insider Bogle Grant C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F1	66,700	$0.00	$0.00

Holdings After Transaction: Stock Option — 66,700 options (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable in equal monthly installments over a three year period commencing on December 9, 2026, and will be fully vested and exercisable on November 9, 2029.

Key Figures

Stock options granted: 66,700 stock options Exercise price: $3.65 per share Vesting commencement: December 9, 2026 +2 more

5 metrics

Stock options granted 66,700 stock options Grant to director Grant C. Bogle on November 9, 2026

Exercise price $3.65 per share Stock options granted to Grant C. Bogle

Vesting commencement December 9, 2026 Equal monthly installments begin

Fully vested and exercisable November 9, 2029 Stock options granted to Grant C. Bogle

Expiration date November 9, 2036 Stock options granted to Grant C. Bogle

Key Terms

equal monthly installments, exercise price, fully vested and exercisable

3 terms

equal monthly installments technical

"vests and becomes exercisable in equal monthly installments"

exercise price financial

"exercise price of $3.65 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully vested and exercisable technical

"fully vested and exercisable on November 9, 2029"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did IMRX director Grant C. Bogle receive?

Grant C. Bogle, a director of Immuneering Corp (IMRX), received 66,700 stock options on November 9, 2026, with an exercise price of $3.65 per share.

When do Grant C. Bogle's IMRX stock options vest and expire?

The options vest in equal monthly installments over a three-year period commencing December 9, 2026. They will be fully vested and exercisable on November 9, 2029, and expire on November 9, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bogle Grant C.

(Last) (First) (Middle)

C/O IMMUNEERING CORPORATION

245 MAIN STREET, SECOND FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$3.65	11/09/2026		A		66,700		(1)	11/09/2036	Class A Common Stock	66,700	$0	66,700	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a three year period commencing on December 9, 2026, and will be fully vested and exercisable on November 9, 2029.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Grant C. Bogle	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)